Read-Gene Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Read-Gene's earnings have been declining at an average annual rate of -66.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 8.5% per year.
Key information
-66.1%
Earnings growth rate
-70.6%
EPS growth rate
| Biotechs Industry Growth | 56.3% |
| Revenue growth rate | 8.5% |
| Return on equity | -29.9% |
| Net Margin | -8.6% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Read-Gene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 12 | -1 | 11 | 0 |
| 31 Mar 24 | 11 | -2 | 11 | 0 |
| 31 Dec 23 | 10 | -1 | 10 | 0 |
| 30 Sep 23 | 9 | -1 | 8 | 0 |
| 30 Jun 23 | 8 | -1 | 7 | 0 |
| 31 Mar 23 | 8 | 0 | 6 | 0 |
| 31 Dec 22 | 7 | 0 | 5 | 0 |
| 30 Sep 22 | 7 | 0 | 6 | 0 |
| 30 Jun 22 | 7 | 0 | 6 | 0 |
| 31 Mar 22 | 6 | 0 | 5 | 0 |
| 31 Dec 21 | 6 | 0 | 5 | 0 |
| 30 Sep 21 | 7 | 0 | 5 | 0 |
| 30 Jun 21 | 7 | 1 | 6 | 0 |
| 31 Mar 21 | 6 | 0 | 5 | 0 |
| 31 Dec 20 | 6 | 0 | 4 | 0 |
| 30 Sep 20 | 6 | 2 | 9 | 0 |
| 30 Jun 20 | 6 | 1 | 6 | 0 |
| 31 Mar 20 | 7 | 1 | 6 | 0 |
| 31 Dec 19 | 6 | 0 | 6 | 0 |
| 30 Sep 19 | 8 | 0 | 6 | 0 |
| 30 Jun 19 | 8 | 0 | 6 | 0 |
| 31 Mar 19 | 7 | 1 | 6 | 0 |
| 31 Dec 18 | 7 | 1 | 6 | 0 |
| 30 Sep 18 | 3 | -1 | 5 | 0 |
| 30 Jun 18 | 4 | -1 | 5 | 0 |
| 31 Mar 18 | 4 | 0 | 5 | 0 |
| 31 Dec 17 | 5 | 0 | 5 | 0 |
| 30 Sep 17 | 6 | -1 | 0 | 0 |
| 30 Jun 17 | 5 | -1 | 0 | 0 |
| 31 Mar 17 | 6 | 0 | 3 | 0 |
| 31 Dec 16 | 5 | 0 | 0 | 0 |
| 30 Sep 16 | 4 | 0 | 3 | 0 |
| 30 Jun 16 | 4 | 0 | 3 | 0 |
| 31 Mar 16 | 2 | -1 | 2 | 0 |
| 31 Dec 15 | 2 | -1 | 3 | 0 |
| 30 Sep 15 | 1 | -1 | 1 | 0 |
| 30 Jun 15 | 1 | -1 | 1 | 0 |
| 31 Mar 15 | 1 | -1 | 1 | 0 |
| 31 Dec 14 | 1 | -1 | 1 | 0 |
| 30 Sep 14 | 0 | -1 | 1 | 0 |
| 30 Jun 14 | 0 | -1 | 1 | 0 |
| 31 Mar 14 | 0 | -1 | 1 | 0 |
| 31 Dec 13 | 0 | -1 | 1 | 0 |
Quality Earnings: RDG is currently unprofitable.
Growing Profit Margin: RDG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RDG is unprofitable, and losses have increased over the past 5 years at a rate of 66.1% per year.
Accelerating Growth: Unable to compare RDG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RDG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: RDG has a negative Return on Equity (-29.87%), as it is currently unprofitable.